Health policy news
European Medicines Agency: EMA has agreed three changes to human medicines for the treatment of cancer in February 2011.
Added: Tuesday 15 March 2011
New marketing authorisations - Docetaxel Teva Pharma (docetaxel) - Treatment of breast cancer, non-small-cell lung cancer and prostate cancer
Withdrawal of marketing authorisation applications - Topotecan SUN (topotecan) - Intended for the treatment of metastatic cancer of the ovary, small-cell lung cancer and cervical cancer
Arbitration procedures (non-safety related) - Docetaxel Teva Generics (docetaxel) - Treatment of: breast cancer, non-small-cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer
More details can be found at:
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: